ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Oral Presentation
Chairs: G. Caramori (Messina, Italy), T. Maes (Ghent, Belgium)

Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation T. Greulich (Marburg, Germany)
Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients. E. Khokhlovich (Cambridge, United States of America)
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY M. Scuri (PARMA, PR, Italy)
Late Breaking Abstract - Lung deflation with Indacaterol/Glycopyrronium improves cardiac function in COPD patients: The CLAIM Study J. Hohlfeld (Hannover, Germany)
Late Breaking Abstract - The first direct comparison between BAL-fluid and the PExA methodology in healthy individuals. A. Behndig (Umeå, Sweden)
Late Breaking Abstract - Activation of Notch1 signalling promotes Bone Marrow-derived Mesenchymal Stem Cells proliferation, migration and survival in COPD microenvironment via PI3K/Akt Y. Cheng (China)
Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies J. Fitzgerald (Vancouver, BC, Canada)
Late Breaking Abstract - Reslizumab vs benralizumab in patients with inadequately controlled asthma: a Bayesian network meta-analysis T. Casale (Tampa, United States of America)